ResMed Inc. (RMD)
- Previous Close
240.66 - Open
238.01 - Bid 242.68 x 800
- Ask 251.95 x 800
- Day's Range
237.77 - 242.47 - 52 Week Range
179.42 - 263.05 - Volume
760,510 - Avg. Volume
1,077,708 - Market Cap (intraday)
35.476B - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
27.03 - EPS (TTM)
8.95 - Earnings Date Jul 30, 2025 - Aug 4, 2025
- Forward Dividend & Yield 2.12 (0.88%)
- Ex-Dividend Date May 8, 2025
- 1y Target Est
264.49
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
www.resmed.co.inRecent News: RMD
View More
Performance Overview: RMD
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RMD
View MoreValuation Measures
Market Cap
35.48B
Enterprise Value
35.38B
Trailing P/E
27.15
Forward P/E
23.26
PEG Ratio (5yr expected)
1.44
Price/Sales (ttm)
7.11
Price/Book (mrq)
6.40
Enterprise Value/Revenue
7.05
Enterprise Value/EBITDA
20.16
Financial Highlights
Profitability and Income Statement
Profit Margin
26.15%
Return on Assets (ttm)
14.01%
Return on Equity (ttm)
25.81%
Revenue (ttm)
5.02B
Net Income Avi to Common (ttm)
1.31B
Diluted EPS (ttm)
8.95
Balance Sheet and Cash Flow
Total Cash (mrq)
944.84M
Total Debt/Equity (mrq)
15.14%
Levered Free Cash Flow (ttm)
1.2B
Research Analysis: RMD
View MoreResearch Reports: RMD
View MoreRaising target price to $250.00
RESMED INC has an Investment Rating of HOLD; a target price of $250.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetResMed Earnings: Solid Device Sales and Gross Margin Expansion
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
RatingPrice TargetResMed's Moat Is Underpinned by Switching Costs and Intangible Brand Assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
RatingPrice TargetWhat does Argus have to say about RMD?
RESMED INC has an Investment Rating of HOLD; a target price of $225.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target